NR 565
ADVANCED PHARMACOLOGY
FINAL EXAM
CONTAINS:
✓ NR 565 Advanced Pharmacology exam-style questions
✓ Multiple-choice questions with correct answers
✓ Detailed rationales for each answer
✓ Graduate-level / Nurse Practitioner pharmacology content
✓ Cardiovascular pharmacology (hypertension, heart failure)
✓ Diabetes and endocrine medications
✓ Renal disease and medication considerations
✓ Antibiotics and anti-infective therapy
✓ Psychiatric and neurologic medications
✓ Pain management pharmacology
✓ Women’s health pharmacologic considerations
✓ Respiratory and gastrointestinal medications
✓ Anticoagulation and emergency pharmacology
,A 55-year-old male patient presents with a blood pressure of 148/92 mmHg on three separate
occasions. He has a history of type 2 diabetes mellitus but no history of cardiovascular disease or
chronic kidney disease. Laboratory results reveal normal renal function and electrolytes. According to
the ACC/AHA guidelines, which of the following is the most appropriate initial pharmacological
treatment for this patient?
A) Hydrochlorothiazide 12.5 mg daily
B) Amlodipine 5 mg daily
C) Lisinopril 10 mg daily
D) Metoprolol succinate 25 mg daily
Correct Answer: C) Lisinopril 10 mg daily
Explanation / Rationale:
The patient has stage 2 hypertension (SBP ≥140 or DBP ≥90) and comorbid type 2 diabetes mellitus.
Guidelines strongly recommend the use of ACE inhibitors (such as lisinopril) or ARBs as first-line
therapy in patients with diabetes because they provide renal protection and reduce the progression of
diabetic nephropathy. While thiazide diuretics and calcium channel blockers are appropriate first-line
agents for the general population, they do not offer the specific renal protective benefits required for
diabetic patients. Beta-blockers are generally not recommended as first-line therapy for
uncomplicated hypertension unless the patient has specific comorbidities such as heart failure or
coronary artery disease.
A 62-year-old female with a history of heart failure with reduced ejection fraction (HFrEF) is currently
experiencing fatigue and shortness of breath upon exertion. She is currently taking no medications.
Which of the following medication classes is associated with a reduction in mortality and is considered
a cornerstone of guideline-directed medical therapy for this patient?
A) Calcium channel blockers
B) Loop diuretics
C) Angiotensin-converting enzyme (ACE) inhibitors
D) Potassium-sparing diuretics
Correct Answer: C) Angiotensin-converting enzyme (ACE) inhibitors
,Explanation / Rationale:
ACE inhibitors (or ARBs if ACE-intolerant) are foundational in the treatment of HFrEF because they
decrease afterload, reduce remodeling, and significantly improve survival rates. Loop diuretics are
essential for symptom management (volume overload) but have not been proven to directly reduce
mortality. Calcium channel blockers (specifically non-dihydropyridines like diltiazem or verapamil) are
generally contraindicated in HFrEF due to negative inotropic effects, while amlodipine is neutral but
not beneficial for survival. Potassium-sparing diuretics are used primarily to counteract hypokalemia
from loop diuretics rather than as a primary mortality-reducing agent.
A 48-year-old male presents with an acute gout flare affecting his left great toe. He has a history of
peptic ulcer disease and renal impairment (eGFR 35 mL/min). Which of the following medications is
the most appropriate choice for treating this acute flare given his comorbidities?
A) Indomethacin 50 mg TID
B) Colchicine 0.6 mg BID (low dose)
C) Prednisone 20 mg daily
D) Naproxen 500 mg BID
Correct Answer: B) Colchicine 0.6 mg BID (low dose)
Explanation / Rationale:
NSAIDs (Indomethacin, Naproxen) are generally contraindicated in patients with significant renal
impairment and a history of peptic ulcer disease due to the risk of worsening renal function and
gastrointestinal bleeding. While systemic corticosteroids are an option, they can cause fluctuations in
blood glucose and other systemic side effects. Colchicine is effective for acute gout flares; however,
the dose must be adjusted for renal impairment. The low-dose regimen (0.6 mg once or twice daily) is
preferred in this population to avoid severe gastrointestinal toxicity and potential
myopathy/neuropathy associated with standard dosing in renal failure.
A 24-year-old female presents with symptoms of a urinary tract infection (dysuria, frequency,
urgency). She is not pregnant and has no known allergies. A urine dipstick confirms the presence of
leukocyte esterase and nitrites. She is otherwise healthy. Which of the following is the most
appropriate first-line empiric treatment?
A) Ciprofloxacin 500 mg BID for 7 days
B) Nitrofurantoin 100 mg BID for 5 days
, C) Trimethoprim/sulfamethoxazole (TMP/SMX) DS BID for 3 days
D) Amoxicillin-clavulanate 875 mg BID for 7 days
Correct Answer: B) Nitrofurantoin 100 mg BID for 5 days
Explanation / Rationale:
Current guidelines recommend Nitrofurantoin as a first-line agent for uncomplicated cystitis due to its
low resistance rates and minimal impact on gut flora. TMP/SMX is also a first-line agent but should be
avoided if local resistance rates exceed 20% or if the patient has taken it within the last 3 months.
Ciprofloxacin is a fluoroquinolone; while effective, it is no longer recommended as first-line for
uncomplicated infections due to the risk of serious adverse effects (tendinitis, aortic rupture) and its
contribution to C. difficile infections. Amoxicillin-clavulanate has poor efficacy in treating E. coli UTIs
and is not recommended.
A 70-year-old male patient with atrial fibrillation (AFib) is being evaluated for anticoagulation therapy.
His CHA₂DS₂-VASc score is 4 (Age 75, HTN, Diabetes, prior TIA). His HAS-BLED score is 3. The patient
expresses concern about the cost of medications and dietary restrictions. Which of the following oral
anticoagulants would be the most appropriate recommendation?
A) Warfarin
B) Dabigatran
C) Rivaroxaban
D) Apixaban
Correct Answer: D) Apixaban
Explanation / Rationale:
While warfarin is low cost, it requires frequent INR monitoring and strict dietary restrictions (vitamin K
intake), which complicates adherence. The patient has a high risk of stroke (CHA₂DS₂-VASc 4) and a
moderate risk of bleeding (HAS-BLED 3). Apixaban has been shown to have a lower risk of major
bleeding compared to warfarin, rivaroxaban, and dabigatran, making it the safest choice for a patient
with an elevated bleeding risk. It is also dosed twice daily without the need for monitoring.
ADVANCED PHARMACOLOGY
FINAL EXAM
CONTAINS:
✓ NR 565 Advanced Pharmacology exam-style questions
✓ Multiple-choice questions with correct answers
✓ Detailed rationales for each answer
✓ Graduate-level / Nurse Practitioner pharmacology content
✓ Cardiovascular pharmacology (hypertension, heart failure)
✓ Diabetes and endocrine medications
✓ Renal disease and medication considerations
✓ Antibiotics and anti-infective therapy
✓ Psychiatric and neurologic medications
✓ Pain management pharmacology
✓ Women’s health pharmacologic considerations
✓ Respiratory and gastrointestinal medications
✓ Anticoagulation and emergency pharmacology
,A 55-year-old male patient presents with a blood pressure of 148/92 mmHg on three separate
occasions. He has a history of type 2 diabetes mellitus but no history of cardiovascular disease or
chronic kidney disease. Laboratory results reveal normal renal function and electrolytes. According to
the ACC/AHA guidelines, which of the following is the most appropriate initial pharmacological
treatment for this patient?
A) Hydrochlorothiazide 12.5 mg daily
B) Amlodipine 5 mg daily
C) Lisinopril 10 mg daily
D) Metoprolol succinate 25 mg daily
Correct Answer: C) Lisinopril 10 mg daily
Explanation / Rationale:
The patient has stage 2 hypertension (SBP ≥140 or DBP ≥90) and comorbid type 2 diabetes mellitus.
Guidelines strongly recommend the use of ACE inhibitors (such as lisinopril) or ARBs as first-line
therapy in patients with diabetes because they provide renal protection and reduce the progression of
diabetic nephropathy. While thiazide diuretics and calcium channel blockers are appropriate first-line
agents for the general population, they do not offer the specific renal protective benefits required for
diabetic patients. Beta-blockers are generally not recommended as first-line therapy for
uncomplicated hypertension unless the patient has specific comorbidities such as heart failure or
coronary artery disease.
A 62-year-old female with a history of heart failure with reduced ejection fraction (HFrEF) is currently
experiencing fatigue and shortness of breath upon exertion. She is currently taking no medications.
Which of the following medication classes is associated with a reduction in mortality and is considered
a cornerstone of guideline-directed medical therapy for this patient?
A) Calcium channel blockers
B) Loop diuretics
C) Angiotensin-converting enzyme (ACE) inhibitors
D) Potassium-sparing diuretics
Correct Answer: C) Angiotensin-converting enzyme (ACE) inhibitors
,Explanation / Rationale:
ACE inhibitors (or ARBs if ACE-intolerant) are foundational in the treatment of HFrEF because they
decrease afterload, reduce remodeling, and significantly improve survival rates. Loop diuretics are
essential for symptom management (volume overload) but have not been proven to directly reduce
mortality. Calcium channel blockers (specifically non-dihydropyridines like diltiazem or verapamil) are
generally contraindicated in HFrEF due to negative inotropic effects, while amlodipine is neutral but
not beneficial for survival. Potassium-sparing diuretics are used primarily to counteract hypokalemia
from loop diuretics rather than as a primary mortality-reducing agent.
A 48-year-old male presents with an acute gout flare affecting his left great toe. He has a history of
peptic ulcer disease and renal impairment (eGFR 35 mL/min). Which of the following medications is
the most appropriate choice for treating this acute flare given his comorbidities?
A) Indomethacin 50 mg TID
B) Colchicine 0.6 mg BID (low dose)
C) Prednisone 20 mg daily
D) Naproxen 500 mg BID
Correct Answer: B) Colchicine 0.6 mg BID (low dose)
Explanation / Rationale:
NSAIDs (Indomethacin, Naproxen) are generally contraindicated in patients with significant renal
impairment and a history of peptic ulcer disease due to the risk of worsening renal function and
gastrointestinal bleeding. While systemic corticosteroids are an option, they can cause fluctuations in
blood glucose and other systemic side effects. Colchicine is effective for acute gout flares; however,
the dose must be adjusted for renal impairment. The low-dose regimen (0.6 mg once or twice daily) is
preferred in this population to avoid severe gastrointestinal toxicity and potential
myopathy/neuropathy associated with standard dosing in renal failure.
A 24-year-old female presents with symptoms of a urinary tract infection (dysuria, frequency,
urgency). She is not pregnant and has no known allergies. A urine dipstick confirms the presence of
leukocyte esterase and nitrites. She is otherwise healthy. Which of the following is the most
appropriate first-line empiric treatment?
A) Ciprofloxacin 500 mg BID for 7 days
B) Nitrofurantoin 100 mg BID for 5 days
, C) Trimethoprim/sulfamethoxazole (TMP/SMX) DS BID for 3 days
D) Amoxicillin-clavulanate 875 mg BID for 7 days
Correct Answer: B) Nitrofurantoin 100 mg BID for 5 days
Explanation / Rationale:
Current guidelines recommend Nitrofurantoin as a first-line agent for uncomplicated cystitis due to its
low resistance rates and minimal impact on gut flora. TMP/SMX is also a first-line agent but should be
avoided if local resistance rates exceed 20% or if the patient has taken it within the last 3 months.
Ciprofloxacin is a fluoroquinolone; while effective, it is no longer recommended as first-line for
uncomplicated infections due to the risk of serious adverse effects (tendinitis, aortic rupture) and its
contribution to C. difficile infections. Amoxicillin-clavulanate has poor efficacy in treating E. coli UTIs
and is not recommended.
A 70-year-old male patient with atrial fibrillation (AFib) is being evaluated for anticoagulation therapy.
His CHA₂DS₂-VASc score is 4 (Age 75, HTN, Diabetes, prior TIA). His HAS-BLED score is 3. The patient
expresses concern about the cost of medications and dietary restrictions. Which of the following oral
anticoagulants would be the most appropriate recommendation?
A) Warfarin
B) Dabigatran
C) Rivaroxaban
D) Apixaban
Correct Answer: D) Apixaban
Explanation / Rationale:
While warfarin is low cost, it requires frequent INR monitoring and strict dietary restrictions (vitamin K
intake), which complicates adherence. The patient has a high risk of stroke (CHA₂DS₂-VASc 4) and a
moderate risk of bleeding (HAS-BLED 3). Apixaban has been shown to have a lower risk of major
bleeding compared to warfarin, rivaroxaban, and dabigatran, making it the safest choice for a patient
with an elevated bleeding risk. It is also dosed twice daily without the need for monitoring.
